PT  - JOURNAL ARTICLE
AU  - Adam Gittins
AU  - Nick Talbott
AU  - Ahmed A Gilani
AU  - Greg Packer
AU  - Richard Browne
AU  - Randeep Mullhi
AU  - Zaheed Khan
AU  - T Whitehouse
AU  - Antonio Belli
AU  - Rajnikant L Mehta
AU  - Fang Gao-Smith
AU  - Tonny Veenith
TI  - Outcomes following acute poor-grade aneurysmal subarachnoid bleed - Is early definitive treatment better than delayed management?
AID  - 10.1101/2020.06.10.20127316
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.10.20127316
4099  - http://medrxiv.org/content/early/2020/06/12/2020.06.10.20127316.short
4100  - http://medrxiv.org/content/early/2020/06/12/2020.06.10.20127316.full
AB  - Background/Objective Patients with poor-grade subarachnoid bleed (pSAH, World Federation of Neurosurgeons grades 4-5) often improve their neurocognitive function months after their ictus. However, it is essential to explore the timing of intervention and its impact on long-term outcome. We compared the long-term outcomes between immediate management within 24 hours (IM) and delayed management after 24 hours (DM) in patients following pSAH.Methods This was a retrospective population-based study, including patients with pSAH who received definitive management between 1st January 2011 and 31st December 2016 in a large tertiary neurocritical care unit. The primary outcome was adjusted odds ratio (OR) of favourable outcome (Glasgow Outcome Scale (GOS) 4-5) for survivors at 12 months following discharge, as measured by the Glasgow Outcome Scale (GOS). The secondary outcomes included adjusted OR of a favourable outcome at discharge, three months and six months following discharge and survival rate at 28 days, three months, six months and 12 months following haemorrhage.Results 111 patients were included in this study: 53 (48%) received immediate management (IM) and 58 (41%) received delayed management (DM). The mean time delay from referral to intervention was 14.9±5.8 hours in IM patients, compared to 79.6±106.1 hours in DM patients. At 12 months following discharge, the adjusted OR for favourable outcome in IM versus DM patients was 0.96 (CI 0.17, 5.39; p=0.961). At hospital discharge, three months and six months, the adjusted OR for favourable outcome was 3.85 (CI 1.38, 10.73; p=0.010), 1.04 (CI 0.22, 5.00; p=0.956) and 0.98 (CI 0.21, 4.58; p=0.982), respectively. There were no differences in survival rate between the groups at 28 days, three months, six months and 12 months (71.7% in IM group vs 82.8% in DM group at 12 months, p=0.163).Conclusions IM and DM after pSAH are associated with similar morbidity and mortality at 12 months. Therefore, delaying intervention in poor-grade patients may be a reasonable approach, especially if time is needed to plan the procedure or stabilise the patient adequately.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNot a clinical TrialFunding StatementNo funding available for this manuscriptAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research used anonymised linked databases and was classed as a service evaluation (CARMS-14561) with a waiver of ethical approval according to the national guidelines (http://www.hra-decisiontools.org.uk/research/docs/definingresearchtable_oct2017-1.pdf) as supported by our institution.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNone required